Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease

Phase 1 Completed 47 enrolled Amgen

RandomizedSequentialQuadruple-blindBasic science

Summary

This study aims to assess the safety and tolerability of AMG 609 when administered subcutaneously as single doses in participants with non-alcoholic fatty liver disease (NAFLD).

Timeline

Start: 2021-05-24
Primary completion: 2023-07-19
Completion: 2023-07-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AMG 609	Unknown	—	Subcutaneous

Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease

Summary

Timeline

Drugs

Indications